Biomarker Insights

Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia

Submit a Paper

Biomarker Insights 2010:5 39-47

Original Research

Published on 12 May 2010

DOI: 10.4137/BMI.S4877

Important Editorial Comment

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Biomarker Insights


We describe the validation of a serum-based test developed by Rules-Based Medicine which can be used to help confirm the diagnosis of schizophrenia. In preliminary studies using multiplex immunoassay profiling technology, we identified a disease signature comprised of 51 analytes which could distinguish schizophrenia (n = 250) from control (n = 230) subjects. In the next stage, these analytes were developed as a refined 51-plex immunoassay panel for validation using a large independent cohort of schizophrenia (n = 577) and control (n = 229) subjects. The resulting test yielded an overall sensitivity of 83% and specificity of 83% with a receiver operating characteristic area under the curve (ROC-AUC) of 89%. These 51 immunoassays and the associated decision rule delivered a sensitive and specific prediction for the presence of schizophrenia in patients compared to matched healthy controls.


PDF  (1011.10 KB PDF FORMAT)


BibTex citation   (BIBDESK, LATEX)


What Your Colleagues Say About Biomarker Insights
I would like to extend my gratitude for creating the next generation of a scientific journal -- the science journal of tomorrow. The entire process bespoke of exceptional efficiency, celerity, professionalism, competency, and service.
Dr Jason B. Nikas (Medical School University of Minnesota, Minneapolis, MN, USA)
More Testimonials

Quick Links

New article and journal news notification services